BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 20823148)

  • 1. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target.
    Plummer R
    Clin Cancer Res; 2010 Sep; 16(18):4527-31. PubMed ID: 20823148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy.
    Plummer ER; Calvert H
    Clin Cancer Res; 2007 Nov; 13(21):6252-6. PubMed ID: 17975135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule PARP modulators--current status and future therapeutic potential.
    Penning TD
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors in cancer therapy: an update.
    Papeo G; Casale E; Montagnoli A; Cirla A
    Expert Opin Ther Pat; 2013 Apr; 23(4):503-14. PubMed ID: 23379721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
    Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
    J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel poly(ADP-ribose) glycohydrolase inhibitors by a quantitative assay system using dot-blot with anti-poly(ADP-ribose).
    Okita N; Ashizawa D; Ohta R; Abe H; Tanuma S
    Biochem Biophys Res Commun; 2010 Feb; 392(4):485-9. PubMed ID: 20079708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.
    Maxmen A
    J Natl Cancer Inst; 2010 Aug; 102(15):1110-1. PubMed ID: 20668266
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
    Nitiss JL
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer.
    Velic D; Couturier AM; Ferreira MT; Rodrigue A; Poirier GG; Fleury F; Masson JY
    Biomolecules; 2015 Nov; 5(4):3204-59. PubMed ID: 26610585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ; Newell DR; Calvert AH; Curtin NJ
    Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cancer therapies based on the inhibition of DNA strand break repair.
    O'Connor MJ; Martin NM; Smith GC
    Oncogene; 2007 Dec; 26(56):7816-24. PubMed ID: 18066095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting DNA repair as a promising approach in cancer therapy.
    Damia G; D'Incalci M
    Eur J Cancer; 2007 Aug; 43(12):1791-801. PubMed ID: 17588740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways.
    Aziz K; Nowsheen S; Georgakilas AG
    Curr Mol Med; 2010 Oct; 10(7):626-39. PubMed ID: 20712589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
    Bryant HE; Helleday T
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):959-61. PubMed ID: 15506935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of poly(ADP-ribose) in the DNA damage signaling network.
    Malanga M; Althaus FR
    Biochem Cell Biol; 2005 Jun; 83(3):354-64. PubMed ID: 15959561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.